HAMILTON, ON and BOSTON, Feb. 26,
2024 /CNW/ -- Fusion Pharmaceuticals Inc. (Nasdaq:
FUSN), a clinical-stage oncology company focused on developing
next-generation radiopharmaceuticals as precision medicines, today
announced that the Company will participate in two upcoming
investor conferences.
- TD Cowen 44th Annual Health Care Conference -
The Company will participate in the "Prostate Cancer Corporate
Panel Discussion" taking place on March 4,
2024, at 10:30 a.m. ET in
Boston, MA. Participating on
behalf of Fusion will be President and Chief Business Officer
Mohit Rawat.
- Leerink Partners 2024 Global Biopharma Conference – The Company
fireside chat presentation will take place on Tuesday, March 12, 2024, at 4:20 p.m. ET in Miami,
FL. Participating on behalf of Fusion will be President and
Chief Business Officer Mohit
Rawat.
Webcasts of each event will be available on the "Events and
Presentations" page in the "Investors & Media" section of the
Company's website at https://ir.fusionpharma.com/events-webcasts. A
replay of the webcast will be archived on the Company's website for
90 days following their respective presentation dates.
About Fusion
Fusion Pharmaceuticals is a clinical-stage oncology company
focused on developing next-generation radiopharmaceuticals as
precision medicines. Fusion connects alpha particle emitting
isotopes to various targeting molecules in order to selectively
deliver the alpha emitting payloads to tumors. Fusion's clinical
portfolio includes: FPI-2265 targeting prostate specific membrane
antigen for metastatic castration resistant prostate cancer
currently in a Phase 2 trial; FPI-1434 targeting insulin-like
growth factor 1 receptor currently in a Phase 1 clinical trial; and
FPI-2059, a small molecule targeting neurotensin receptor 1,
currently in a Phase 1 trial. In addition to a robust proprietary
pipeline, Fusion has a collaboration with AstraZeneca to jointly
develop novel targeted alpha therapies (TATs) and combination
programs between Fusion's TATs and AstraZeneca's DNA Damage
Response Inhibitors and immuno-oncology agents. The Company
received IND clearance for FPI-2068, the first novel TAT under the
collaboration, which targets EGFR-cMET. Fusion has also entered
into a collaboration with Merck to evaluate FPI-1434 in combination
with Merck's KEYTRUDA® (pembrolizumab) in patients with solid
tumors expressing IGF-1R. Fusion has a Good Manufacturing Practice
compliant radiopharmaceutical manufacturing facility designed to
support manufacturing of the Company's growing pipeline of TATs.
The Company has signed strategic actinium supply agreements with
Niowave, Inc. and BWXT Medical.
Contact:
Amanda
Cray
Senior Director of Investor Relations & Corporate
Communications
(617) 967-0207
cray@fusionpharma.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/fusion-pharmaceuticals-to-present-at-upcoming-march-investor-conferences-302070120.html
SOURCE Fusion Pharmaceuticals
